17年啃下“硬骨头”！她用1600次失败换取领跑地位

Core Viewpoint - The article highlights the journey of Shanxi Jinbo Biopharmaceutical Co., Ltd. and its founder Yang Xia, who has dedicated 17 years to developing recombinant type III humanized collagen technology, achieving a breakthrough in "zero immune rejection" and positioning China as a leader in the "life materials" sector [1][12][17]. Group 1: Industry Challenges and Innovations - The article identifies the long-standing challenges in the animal collagen industry, particularly the issue of immune reactions, which has hindered progress for over a century [4][6]. - Yang Xia's approach focuses on overcoming three major obstacles: immune response, virus risk, and purification difficulties, which are seen as significant barriers to industry advancement [6][7]. - The company aims to shift from imitation to original innovation, emphasizing the need for proprietary technology rather than mere replicas in the Chinese industry [7][11]. Group 2: Breakthroughs and Achievements - A pivotal moment for the company occurred in 2018 when the team identified the key structural parameter of recombinant type III humanized collagen, which is 164.88°, marking a significant advancement in understanding this life material [11]. - The company has faced over 1,600 failures in its research journey, but ultimately recognized the self-assembly characteristics of collagen, which helped change perceptions in the medical community [11][12]. - Jinbo has now become a standard setter in the industry, with the international standard for recombinant humanized collagen officially established in April 2025 [12][17]. Group 3: Future Vision and Goals - Yang Xia envisions the company as a "pioneer in life materials," aiming to solidify its global lead and become a top player in the biomaterials sector within the next 10-20 years [15][17]. - The company maintains a sense of urgency and competitive spirit, recognizing the need for continuous innovation to sustain its advantages in the market [15][17]. - The narrative of Jinbo's transformation from a "shell company" to an international standard setter exemplifies the broader trend of China's biopharmaceutical industry moving from a follower to a leader [17].